Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under... Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014.
- Mechanism
- Curator reviewed
Finafloxacin is a fluoroquinolone antibiotic, which selectively inhibit bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair and recombination.
- Primary indication
- Finafloxacin is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older.Curator reviewed · 1 structured indication
- Formula / weight
- C20H19FN4O4 · 398.394 g/mol (avg)
- First approval
- Canada, 2019
- Also known as
- gastrochinolon · gastroquinolone
- Code names
- AL-60371 · BY-377
Resolves to
FYMHQCNFKNMJAV-HOTGVXAUSA-NSMILES[H][C@]12CN(C[C@]1([H])OCCN2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1C#N)C(O)=OWhat you can answer from here — as of October 01, 2026
Which drugs share a target with Finafloxacin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account